vorinostat has been researched along with Necrosis in 4 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Necrosis: The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
Excerpt | Relevance | Reference |
---|---|---|
" We report on a 51-year-old patient with tumor-stage mycosis fungoides who developed several unusual features such as extensive necrosis of lymphoma lesions, granulomatous reaction, and venular thromboses while under treatment with bexarotene, vorinostat, and high-dose fenofibrate." | 7.74 | Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate. ( Assaf, C; Beyer, M; Lukowsky, A; Roewert-Huber, J; Steinhoff, M; Sterry, W, 2008) |
" We report on a 51-year-old patient with tumor-stage mycosis fungoides who developed several unusual features such as extensive necrosis of lymphoma lesions, granulomatous reaction, and venular thromboses while under treatment with bexarotene, vorinostat, and high-dose fenofibrate." | 3.74 | Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate. ( Assaf, C; Beyer, M; Lukowsky, A; Roewert-Huber, J; Steinhoff, M; Sterry, W, 2008) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 3 (75.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Wang, D | 1 |
Zhao, M | 1 |
Chen, G | 1 |
Cheng, X | 1 |
Han, X | 1 |
Lin, S | 1 |
Zhang, X | 1 |
Yu, X | 1 |
Lai, F | 1 |
Guo, ST | 1 |
Jin, L | 1 |
Jiang, CC | 1 |
Wang, CY | 1 |
Croft, A | 1 |
Chi, MN | 1 |
Tseng, HY | 1 |
Farrelly, M | 1 |
Atmadibrata, B | 1 |
Norman, J | 1 |
Liu, T | 1 |
Hersey, P | 1 |
Zhang, XD | 1 |
Booth, L | 1 |
Roberts, JL | 1 |
Conley, A | 1 |
Cruickshanks, N | 1 |
Ridder, T | 1 |
Grant, S | 1 |
Poklepovic, A | 1 |
Dent, P | 1 |
Steinhoff, M | 1 |
Beyer, M | 1 |
Roewert-Huber, J | 1 |
Lukowsky, A | 1 |
Assaf, C | 1 |
Sterry, W | 1 |
4 other studies available for vorinostat and Necrosis
Article | Year |
---|---|
The histone deacetylase inhibitor vorinostat prevents TNFα-induced necroptosis by regulating multiple signaling pathways.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Autophagy; CASP8 and FADD-Like Apoptosis Regulatin | 2013 |
Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Synergism; Gene Knockdown Tech | 2013 |
HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Fem | 2014 |
Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate.
Topics: Acute Disease; Anticarcinogenic Agents; Bexarotene; Biopsy; Drug Eruptions; Female; Fenofibrate; Fev | 2008 |